The importance of albuminuria in primary health care: prevention is better than cure
DOI:
https://doi.org/10.32385/rpmgf.v41i5.14075Keywords:
Diabetes mellitus, Hypertension, Primary health care, Chronic kidney disease, AlbuminuriaAbstract
This article discusses a study conducted in a Family Health Unit that assessed the follow-up of 126 patients with hypertension and/or diabetes mellitus, focusing on the determination of microalbuminuria, a significant marker of kidney disease and cardiovascular risk. The results showed that in most patients, albuminuria was measured annually using the albumin-to-creatinine ratio (ACR) in a random urine sample. Regarding nephroprotective and albuminuria-reducing therapies, angiotensin-converting enzyme inhibitors (ACEIs) were the preferred agents, while sodium-glucose cotransporter-2 inhibitors (SGLT2i) were used only in patients with higher ACR levels. Given the high prevalence of chronic kidney disease in Portugal, we consider it is extremely relevant to raise awareness about the importance of assessing albuminuria in primary health care to detect early signs of worsening renal function and initiate prognosis-modifying therapies.
Downloads
References
1. Sociedade Portuguesa de Nefrologia. Dados gerais do registo: tratamento de doença renal crónica terminal em Portugal, 2021. Lisboa: SPN; 2021.
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-S314.
3. Marques da Silva P, Carvalho D, Nazaré J, Martins L, Aguiar C, Manso MC, et al. Prevalence of microalbuminuria in hypertensive patients with or without type 2 diabetes in a Portuguese primary care setting: the RACE (micRoAlbumin sCreening survEy) study. Rev Port Cardiol. 2015;34(4):237-46.
4. Ruilope LM, Ortiz A, Lucia A, Miranda B, Alvarez-Llamas G, Barderas MG, et al. Prevention of cardiorenal damage: importance of albuminuria. Eur Heart J. 2023;44(13):1112-23.
5. American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S175-84. Erratum in: Diabetes Care. 2022;45(3):758. Diabetes Care. 2022;45(9):2182-4.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1-S127.
7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. Erratum in: Eur Heart J. 2019;40(5):475.
8. Tangri N, Ferguson TW, Wiebe C, Eng F, Nash M, Astor BC, et al. Validation of the kidney failure risk equation in kidney transplant recipients. Can J Kidney Health Dis. 2020;7:2054358120922627.
9. Silva BM, Charreu J, Duarte I, Outerelo C, Gameiro J. Validation of the kidney failure risk equation in a Portuguese cohort. Nefrologia (Engl Ed). 2023;43(4):467-73.
10. Santos-Araújo C, Mendonça L, Carvalho DS, Bernardo F, Pardal M, Couceiro J, et al. Twenty years of real-world data to estimate chronic kidney disease prevalence and staging in an unselected population. Clin Kidney J. 2022;16(1):111-24.
11. Vinhas J, Aires I, Batista C, Branco P, Brandão J, Nogueira R, et al. RENA study: cross-sectional study to evaluate CKD prevalence in Portugal. Nephron. 2020;144(10):479-87.
12. Shlipak MG, Tummalapalli SL, Boulware LE, Grams ME, Ix JH, Jha V, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2021;99(1):34-47.
13. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD, et al. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med. 2016;129(2):153-162.e7.
14. Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-46.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Portuguese Journal of Family Medicine and General Practice

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.